APOA5 and metabolic dysfunction-associated steatotic liver disease: PCSK7 has been involved in lowering ApoA-V levels (Ashraf et al., 2020) and recently a genetic variant in PCSK7 was associated with dyslipidemia and NAFLD (Dongiovanni et al., 2019).